UK: Integrated Care Systems – lessons and outlook from the first six months

Published on February 27, 2023

In July 2022, Integrated Care Systems (ICSs) became the statutory bodies responsible for commissioning medicines and budget allocation, replacing Clinical Commissioning Groups (CCGs). In this article, we review the key budget- and funding-related challenges, the outlook for 2023, and implications for therapies preparing to launch in the UK.

UK financial environment

The current UK healthcare environment reflects long-standing resource constraints, compounded by an acute stressor in the pandemic, which has caused a system-wide backlog for non-urgent, elective care services, quality of care concerns such as poorer patient outcomes (e.g., time-pressured treatment), and delays in emergency services. Financial experts including NHS England’s Chief Financial Officer, Julian Kelly, are warning of pressure for efficiency savings and troubled times ahead for the NHS due, in part, to the economic challenges brought on by inflation…

Continue reading on website
Other news

Pharma: Brand planning season starts now!

February 23, 2023
Every year, healthcare companies go through the same procedures developing brand plans for their products.However, despite the yearly repetition, processes, expectations, and templates are often not quite as aligned as some would think. Based on our survey of 73 brand planning experts across the globe (marketing VPs, marketing directors, brand managers, etc.) we identified five key topics that hea

Spain: Pharmaco-economic analyses and their implications

February 27, 2023
Pharmaco-economic analyses are gaining momentum in Spain, but what are the potential implications? In the recent revisions issued by the Spanish health authorities, the inclusion of an economic analysis in the Therapeutic Positioning Reports (IPTs) is required leading to a more comprehensive evaluation of the therapy prior to price and reimbursement (P&R) negotiations. Our experts Ana Mozetic, Pat